THERAPY-RELATED ACUTE MYELOGENOUS LEUKEMIA ASSOCIATED WITH 11Q23 CHROMOSOMAL-ABNORMALITIES AND TOPOISOMERASE-II INHIBITORS - REPORT OF 4 ADDITIONAL CASES AND BRIEF COMMENTARY

被引：13
作者：
BREDESON, CN [1 ]
BARNETT, MJ [1 ]
HORSMAN, DE [1 ]
DALAL, BI [1 ]
RAGAZ, J [1 ]
PHILLIPS, GL [1 ]
机构：
[1] VANCOUVER GEN HOSP,LEUKEMIA BONE MARROW TRANSPLANTAT PROGRAM BRITISH COLUMBIA,DIV HEMATOL,VANCOUVER V5Z 4E3,BC,CANADA
来源：
LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期
关键词：
THERAPY-RELATED AML; 11Q23 CHROMOSOMAL ABNORMALITIES; TOPOISOMERASE-II INHIBITORS; EPIPODOPHYLLOTOXINS;
D O I：
10.3109/10428199309054742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report 4 additional cases of therapy-related acute myelogenous leukemia (t-AML) with the translocation t(9;11)(p22q23). Chemotherapy for the primary malignancy (breast carcinoma in 2, non-Hodgkin's lymphoma in 2) included agents with topoisomerase II inhibitory activity (doxorubicin in 2; doxorubicin and etoposide in 1; doxorubicin, etoposide and mitoxantrone in 1) as well as alkylators. In agreement with previous reports, the leukemia was monoblastic (FAB M5 subtype) in all 4 patients, with only 1 having prior myelodysplasia, and the latency period from primary therapy was relatively short (24-48 months). All patients received potentially curative treatment for the leukemia which included allogeneic bone marrow transplantation in 3; however, all died (3 of t-AML and 1 of lymphoma). Therapy-related AML associated with exposure to agents with topoisomerase II inhibitory activity (epipodophyllotoxins and anthracyclines) is a distinct entity, the genetic basis and optimal treatment of which remain to be determined.
引用
收藏
页码：141 / 145
页数：5
相关论文
共 55 条
  • [1] Arseneau J.C., Sponzo R.W., Levin D.L., Schnipper L.E., Bonner H., Young R.C., Canellos G.P., Johnson R.E., Devita V.T., Nonlymphomatous malignant tumors complicating Hodgkin's disease, N. Engl. J. Med., 287, pp. 1119-1122, (1972)
  • [2] Coleman C.N., Williams C.J., Flint A., Glatstein E.J., Rosenberg S.A., Kaplan H.S., Hematologic neoplasia in patients treated for Hodgkin's disease, N. Engl. J. Med., 297, pp. 1249-1252, (1977)
  • [3] Glicksman A.S., Pajak T.F., Gottlieb A., Nissen N., Stutzman L., Cooper M.R., Second malignant neoplasms in patients successfully treated for Hodgkin's disease: A Cancer and Leukemia Group B study, Cancer Treat. Rep., 66, pp. 1035-1044, (1982)
  • [4] Michels S.D., McKenna R.W., Arthur D.C., Brun-Ning R.D., Therapy-related acute myeloid leukemia and myelodysplastic syndrome: A clinical and morphologic study of 65 cases, Blood, 65, pp. 1364-1372, (1985)
  • [5] Kantarjian H.M., Keating M.J., Walters R.S., Smith T.L., Cork A., McCredie K.B., Freireich E.J., Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features, J. Clin. Oncol., 4, pp. 1748-1757, (1986)
  • [6] Curtis R.E., Boice J.D., Moloney W.C., Ries L.G., Flannery J.T., Leukemia following chemotherapy for breast cancer, Cancer Res., 50, pp. 2741-2746, (1990)
  • [7] Pedersen-Bjergaard J., Philip P., Pedersen N.T., Hou-Jen-Sen K., Svejgaard A., Jensen G., Nissen N.I., Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients, Cancer, 54, pp. 452-462, (1984)
  • [8] Arthur D.C., Bloomfield C.D., Banded chromosome analysis in patients with treatment-associated acute nonlymphocytic leukemia, Cancer Genet. Cyrogenet., 12, pp. 189-199, (1984)
  • [9] Preisler H.D., Early A.P., Raza A., Vlahides G., Mar-Inello M.J., Stein A.M., Browman G., Therapy of secondary acute nonlymphocytic leukemia with cytar-abine, N. Engl. J. Med., 308, pp. 21-23, (1983)
  • [10] Vaughan W.P., Karp J.E., Burke P.J., Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy, J. Clin. Oncol., 1, pp. 204-207, (1983)
123456